In patients with non-ST-elevation acute coronary syndrome (NSTE- ACS), pre-treatment with the P2Y12 antagonist prasugrel prior to catheterization, significantly increases the risk of life-threatening bleeding without reducing the risk of major ischemic events, according to the results of the ACCOAST (A Comparison of prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction) trial.
Amsterdam, The Netherlands, Sunday 1 September 2013: In patients with non-ST-elevation acute coronary syndrome (NSTE- ACS), pre-treatment with the P2Y12 antagonist prasugrel prior to catheterization, significantly increases the risk of life-threatening bleeding without reducing the risk of major ischemic events, according to the results of the ACCOAST (A Comparison of prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction) trial.
The findings point to a "paradigm shift" away from pre-treatment in such patients which will not only be "hard to believe and destabilizing for many cardiologists, but may also be difficult to implement since the routine use of pre-treatment has been anchored for so long," said the study's lead investigator Gilles Montalescot, from the ACTION study group at the Institut de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpêtriėre, in Paris, France.
Current ESC and ACCF/AHA guidelines recommend that pre-treatment with P2Y12 inhibitors should be added to aspirin as soon as possible before catheterization and maintained over 12 months, unless there are contraindications such as excessive risk of bleeding, explained Dr. Montalescot.
This strategy has been accepted for years based on the results of observational, subgroup and non-randomized analyses performed with the older drug clopidogrel,
But newer P2Y12 receptor antagonists such as prasugrel are more potent and have a faster onset of action, which makes these drugs well-adapted to PCI.
"With the rapid onset of action of the oral and intravenous P2Y12 inhibitors and the modern era of short delays between hospital admission and catheterization, the risk of an ischemic complication before catheterization is extremely low, suggesting that there is no longer a need for pre-treatment in NSTE-ACS patients to prevent ischemic complications while waiting for catheterization," he said.
"Moreover, there is also no benefit of pre-treatment on peri-PCI complications. Together, our findings suggest use of prasugrel should be considered only after the coronary anatomy has been defined."
Enrolment for ACCOAST was suspended by an independent data monitoring committee on November 16, 2012 when a planned interim analysis showed that pre-treatment with prasugrel was associated with an increased risk of major and life-threatening bleeding, although no increased rate of mortality.
The phase 3, randomized, double blind, event-driven study conducted in 171 centers and 19 countries in Europe, Canada, Israel and Turkey, randomized 4033 patients to either pre-treatment with prasugrel or placebo at the time of NTSE-ACS diagnosis (n=2037) followed by prasugrel given selectively after the coronary angiogram to patients with a confirmed indication for PCI (n=1996). Patients in both arms also received aspirin and standard of care. Patients were to be scheduled to undergo coronary angiography/PCI within 48 hours from randomization. Patients In the pre-treatment arm received a 30-mg loading dose (LD) of prasugrel at the time of randomization and, if PCI was indicated, an additional 30-mg at the time of PCI, while patients in the no pre-treatment arm got a placebo dose at randomization, and, if PCI was indicated, a 60-mg LD of prasugrel at the time of PCI.
Ultimately, PCI was performed in 68.7% of subjects, while in the 7 days post-randomization coronary artery bypass surgery (CABG) was chosen for 6.2% and medical management for 25.1%.
For the primary endpoint, a composite of cardiovascular death, myocardial infarction, stroke, urgent revascularization or GPIIb/IIIa bailout at 7 and 30 days post-randomization, there was no significant difference between the pre-treatment and no pre-treatment groups (10.0% vs 9.8%, p = 0.812, and 10.8 vs 10.8, p = 0.976, respectively). However, the rate of all major bleeding, according to Thrombolysis in Myocardial Infarction (TIMI) criteria was almost double in the pre-treatment group at both 7 days (2.6% vs 1.4%, p = 0.006), and 30 days (2.9% vs 1.5%, p = 0.002). At 7 days, major and life-threatening TIMI bleeding not related to CABG procedures were increased by three-fold and six-fold respectively (1.33% vs 0.45%, p = 0.003; and 0.83% vs 0.15%, p = 0.002).
There was however, no excess of fatal or intracranial hemorrhage with pre-treatment. ACCOAST is the first randomized study of pre-treatment versus no pre-treatment in NSTE ACS before scheduled catheterization, said Dr. Montalescot. While the study looked specifically at prasugrel, the results, when considered alongside another recent study of pre-treatment with clopidogrel (JAMA. 2013;309(14):1461) are potentially applicable to the global concept of pre-treatment with a P2Y12 inhibitor.
DISCLOSURES: Gilles Montalescot reports: research grants to the institution or consulting/lecture fees from Abbott Vascular, Accumetrics, AstraZeneca, Bayer, Biotronik, BMS, Boehringer-Ingelheim, Daiichi-Sankyo, Duke Institute, Eli Lilly and Company, Europa, Fédération Française de Cardiologie, Fondation de France, GSK, INSERM, Institut de France, Iroko, Lead-up, Menarini, Medtronic, Nanospheres, Novartis, Pfizer, Roche, Sanofi-Aventis, Stentys, Société Française de Cardiologie, Springer, The Medicines Company, The TIMI group, WebMD, and Wolters.
Leonardo Bolognese reports receiving board membership from Eli Lilly and Company, Daiichi Sankyo, and consulting or lecture fees from Eli Lilly and Company, Daiichi Sankyo, Menarini Ind Farma, Abott, AstraZeneca, Iroko Cardio Int.
Dariusz Dudek reports receiving consulting and lecture fees from Abbott, Adamed, Adyton Medical Polska, Abiomed Europe, AstraZeneca, Biotronik, Balton, Bayer, BBraun, BioMatrix, Boston Scientific, Boehringer Ing., Bracco, Bristol-Myers Squibb, Comesa Polska, Cordis, Cook, Covidien Polska Sp. z o. o., DRG MedTek, Eli Lilly, EuroCor, GE Hammermed, Healthcare, Glaxo, Inspire-MD, Iroko Cardio International, Medianet Sp. z o.o., Medtronic, Medicines Company, Meril Life Sciences, MSD, Orbus-Neich, Pfizer, Possis, ProCardia Medical, Promed, REVA Medical, Sanofi-Aventis, Siemens, Solvay, Stentys, St. Jude Medical, Terumo, Tyco, Volcano.
Patrick Goldstein reports receiving speaker fees from Sanofi-Aventis, Eli Lilly and Company, Daiichi Sankyo, Boehringer, AstraZeneca, The Medicines Company, Bayer and is a member of steering and executive committee for Eli Lilly and Company, The Medicines Company, and Boehringer Ingelheim.
Christian Hamm reports receiving consulting or speaker fees from Eli Lilly and Company, Abbott Vascular, Bayer, Boehringer Ingelheim, Boston Scientific, Cordis, Daiichi Sankyo, GlaxoSmithKline, Medtronic, Pfizer, Merck, Roche Diagnistics, Correvio, Sanofi-Aventis, AstraZeneca and The Medicines Comp and is a board member for AstraZeneca, Medtronic, and Boehringer Ingelheim.
Jean-Francois Tanguay reports grants from Abbott Vascular, Eli Lilly and Company, AstraZeneca, Roche, GlaxoSmithKline, lecture fees from Sanofi, Pfizer, BMS, Eli Lilly and Company, AstraZeneca, Abbott Vascular and consultancy from Eli Lilly and Company, AstraZeneca, Abbott Vascular, GlaxoSmithKline, and Rome.
Jurrien M ten Berg reports Astrazeneca board membership, consultancy for Eli Lilly and Company, Astrazeneca and Merck, lecture fees for Eli Lilly and Company, and Astra Zeneca. Debra Miller, Timothy Costigan, Jochen Goedicke and Joseph A Jakubowski are employees of Eli Lilly and Company.
Johanne Silvain reports receiving research grants from, Brahms, Daiichi-Sankyo, Eli Lilly, INSERM, Fédération Française de Cardiologie and Société Française de Cardiologie Sanofi-Aventis; consultant fees from Astra Zeneca, Daiichi-Sankyo, The Medecine Company, Stentys and Eli Lilly and company; and lecture fees from Astra Zeneca, AAZ, Boehringer Ingelheim, Cordis, Daiichi-Sankyo, Eli Lilly and Company, and Iroko Cardio.
Luigi Oltrona Visconti, Margit Niethammer, Zuzana Motovska and Paolo Angioli reports no conflicts of interest.
Jacek Legutko reports receiving a research grant from ICON reserach, lectures fees and reimbursement for travel/accommodations/meeting expenses from Eli Lilly and Company, lecture fees from Astra Zeneca.
Guillaume Cayla reports consulting for Astra Zeneca, Eli Lilly and Company, Daiichi Sankyo, Abbott, lecture fees for Abbott Vascular, Astra Zeneca, BMS, Daiichi Sankyo, Eli Lilly and Company, CLS Behring, Boehrinhger Ingelheim, Bayer, Pfizer, Iroko Cardio, Novartis.
Petr Widimsky reports receiving consulting and speaker fees from Eli Lilly and Company and Daiichi Sankyo.
This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2013. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.More information on the ESC Press Conference page: Hot Line II: Late Breaking Trials on Intervention and devices
About the European Society of CardiologyThe European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe. About ESC Congress 2013The ESC Congress is currently the world’s premier conference on the science, management and prevention of cardiovascular disease. The spotlight of this year's event is "The Heart Interacting with Systemic Organs". ESC Congress 2013 takes place from 31 August to 4 September at the RAI centre in Amsterdam, Netherlands. More information on ESC Congress 2013 contact the ESC Press Office.
Our mission: To reduce the burden of cardiovascular disease.
© 2019 European Society of Cardiology. All rights reserved.